You are here

Marek Nagiec


Nagiec MM, Skepner AP, Negri J, et al. Modulators of hepatic lipoprotein metabolism identified in a search for small-molecule inducers of tribbles pseudokinase 1 expression. PLoS One. 2015 Mar 26;10(3):e0120295. 

Schnute ME, McReynolds MD, Kasten T et al. Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1. Biochem J. 2012 May 15;444(1):79-88. Featured in: Lynch KR. (2012) Building a better sphingosine kinase-1 inhibitor. Biochem J. 444(1):e1-2.

Nagiec MM, Skrzypek M, Nagiec EE et al. The LCB4 (YOR171c) and LCB5 (YLR260w) genes of Saccharomyces encode sphingoid long chain base kinases. J Biol Chem. 1998 Jul 31;273(31):19437-42.

Marek Nagiec, Ph.D.

Marek M. Nagiec is a group leader/research scientist in the Translational Research Group at the Stanley Center for Psychiatric Research at Broad Institute. He develops and leads chemical biology projects that aim to translate advances in human disease genetics into novel therapeutics. The approaches include both specific target centered efforts as well as phenotypic screens.

Currently, Nagiec focuses on identification of modulators of postsynaptic signaling and dendritic spine remodeling for development of novel treatments for psychiatric diseases. His key areas of expertise include therapeutic lead discovery and development, cellular and biochemical assay development, phenotypic screens, interrogation of lipid metabolic and signaling pathways, and S1P signaling in CNS. Additional skill sets include molecular biology, genetic and biophysical approaches to target ID, and small G-protein signaling and PPI assays to probe neuronal function.

Nagiec obtained his Ph.D. in molecular biology from the Department of Genetics at Warsaw University, Poland, and he received postdoctoral training at the Department of Biochemistry at University of Kentucky Medical School, where he studied sphingolipid signaling and metabolic pathways. Subsequently he worked as head of the antifungal discovery lab at Pharmacia Corp., and later as a senior principal scientist at Pfizer Inc., leading a group and the drug discovery projects in the Inflammation and Immunology Research Unit. He joined the Broad Institute in 2010.

Contact Marek M. Nagiec by email at

October 2015